EARS Faces The Music, ABIO On Track, TEVA Gets EU Nod For Asthma Drug

Shares of Auris Medical Holding AG (EARS) cratered over 59% on Thursday as the phase III trial of Keyzilen in acute inner ear tinnitus failed to meet its co-primary efficacy endpoints.

from RTT - Biotech http://ift.tt/2bk8gr7
via IFTTT